the impact of hyperbaric oxygen therapy on serological values of vascular endothelial growth factor (vegf) and basic fibroblast growth factor (bfgf)高压氧治疗对血清血管内皮生长因子(vegf)的价值观和基本成纤维细胞生长因子(bfgf).pdf

Jung et al. Head Face Medicine 2010, 6:29 /content/6/1/29 HEAD FACE MEDICINE RESEARCH Open Access The impact of hyperbaric oxygen therapy on serological values of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) 1 1 2 3 1* Susanne Jung , Kai Wermker , Harald Poetschik , Thomas Ziebura , Johannes Kleinheinz Abstract Background: Hyperbaric oxygen (HBO) therapy is an effective adjunct treatment for ischemic disorders such as chronic infection or chronic wounds. It combines hyperoxic effects with the stimulating potential of post- therapeutic reactive hypoxia. As its crucial effects, stimulation of fibroblast growth, induction of collagen synthesis and the initiation of angiogenesis are discussed. Angiogenesis is a multistage process resulting in the growth of blood vessels. It includes degradation of extracellular matrix, proliferation and migration of different cell populations and finally formation of new vessel structures. This complex chain of procedures is orchestrated by different cytokines and growth factors. Crucial mediators of angiogenesis are basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF); their in-vivo function is still not fully understood. Methods: Forty-three patients suffering from sudden sensorineural hearing loss or tinnitus were treated with HBO. The therapy included 10 sessions of 90 minutes each, one session a day. Serological levels of bFGF and VEGF were assessed by enzyme-linked immunosorbent assays performed according to the manufacturer’s instructions on day 1, 2, 5 and 10 of HBO therapy and were compared to mean va